Effectiveness of CAR-T treatment toward the potential risk of second malignancies

Front Immunol. 2024 May 2:15:1384002. doi: 10.3389/fimmu.2024.1384002. eCollection 2024.

Massimo Martino^{1

2}, Gaetana Porto^{1

2}, Giorgia Policastro^{1

2}, Caterina Alati^{2

3}, Barbara Loteta^{1

2}, Maria Caterina Micó^{1

2}, Clizia Argiró^{1

2}, Maria Altomonte^{2

4}, Tiziana Moscato^{1

2}, Demetrio Labate^{2

5}, Vincenzo Dattola^{2

6}, Carmelo Massimiliano Rao^{2

7}, Francesca Cogliandro^{1

2}, Filippo Antonio Canale^{1

2}, Virginia Naso^{1

2}, Gianfranco Filippelli⁸, Antonino Iaria⁹, Martina Pitea^{1

2}

¹ Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli,", Reggio Calabria, Italy.
² CAR-T Multidisciplinary Team, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli,", Reggio Calabria, Italy.
³ Hematology Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁴ Pharmacy Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁵ ICU Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁶ Neurology Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁷ Cardiology Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁸ Oncology Department, Hospital of Paola, Cosenza, Italy.
⁹ Oncology Unit, Melito Porto Salvo, Reggio Calabria, Italy.

No abstract available

Keywords: car-t; follow-up; malignancies; second cancer; therapy.

MeSH terms

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.